The impact of diabetes mellitus and glycemic control on clinical outcomes following liver transplant for hepatitis C. (20th June 2014)

• Record Type: Journal Article
• Authors: Morbitzer, Kathryn A.; Taber, David J.; Pilch, Nicole A.; Meadows, Holly B.; Fleming, James N.; Bratton, Charles F.; McGillicuddy, John W.; Baliga, Prabhakar K.; Chavin, Kenneth D.
• Is Part Of: Clinical transplantation. Volume 28:Number 8(2014)
• Page Start: 862
• Page End: 868
• Publication Date: 2014-06-20
• Subjects: Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ctr.12391
• Languages: English
• ISSNs: 0902-0063

Abstract

<abstract abstract-type="main" id="ctr12391-abs-0001"> <title>Abstract</title> <p>Hepatitis C is the leading indication for liver transplantation in the USA and recurrence is universal. The impact of preexisting diabetes, new‐onset diabetes after transplant (NODAT), and glycemic control on fibrosis progression has not been studied. This retrospective longitudinal cohort study included adult liver recipients with hepatitis C transplanted between 2000 and 2011. Patients were divided into three groups: preexisting diabetes (n = 41), NODAT (n = 59), and no diabetes (n = 103). Patients with preexisting diabetes (70%) or NODAT (59%) were more likely to develop hepatitis C recurrence (≥stage 1 fibrosis), as compared to non‐diabetics (36%, p = 0.006). There was also a trend toward a higher incidence of at least Stage 2 fibrosis (36% and 48% vs. 23%, respectively; p = 0.063). Patients with tight glycemic control had a lower rate of Stage 2 fibrosis development (78% vs. 60%, p = 0.027), while those with good control (&lt;150 mg/dL) also had lower rates of Stage 2 fibrosis (84% vs. 62%, p = 0.004). Multivariable analysis verified a decreased rate of recurrence for patients with blood glucose &lt;138 mg/dL (p = 0.021), after controlling for confounders. These results demonstrate that diabetes is strongly associated with an increased risk of hepatitis C virus‐related fibrosis development and glycemic control may reduce the risk and severity of recurrence.</p> </abstract>